AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03707106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: progressive muscle relaxation
Description: Progressive muscle relaxation for unspecific stress reduction
Study NCT03247608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambio Health Remote Monitoring
Description: Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
Study NCT03805763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large extent of ILM Peeling
Description: The extent of ILM peeling is 4DD
Study NCT03805763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small extent of ILM Peeling
Description: The extent of ILM peeling is 2DD
Study NCT02696382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive High Intensity Therapy (PHIT)
Description: Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program.
Study NCT02696382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program.
Study NCT01447069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
Study NCT00694226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivational intervention
Description: Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
Study NCT00694226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
Study NCT02096406 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACE/ARB continuation
Description: ACE/ARB will be taken the morning of surgery with a sip of water
Study NCT02096406 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACE/ARB withdrawal
Description: ACE/ARB will be stopped 48 hours prior to surgery
Study NCT01993290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
Study NCT01483495 — intervention group
Intervention type: DEVICE
Intervention: Diffuse optical spectroscopy
Description: Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
Study NCT03929549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RCMP titration
Description: An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
Study NCT01617161 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Therapy
Description: 5 days per week up to 9 weeks
Study NCT01617161 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: 5 times per week up to 9 weeks
Study NCT02470325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avidekel oil
Description: Avidekel cannabis oil 6:1 CBD:THC
Study NCT01985555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib(HMPL-504)
Description: Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
Study NCT04312711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-TOF-MRA
Description: The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases.
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Loxapine 0.625 mg
Description: Single 0.625 mg (lowest) dose of inhaled loxapine
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Loxapine 1.25 mg
Description: Single 1.25 mg (2nd) dose of inhaled loxapine
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Loxapine 2.5 mg
Description: Single 2.5 mg (3rd) dose of inhaled loxapine
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Loxapine 5 mg
Description: Single 5 mg (4th) dose of inhaled loxapine
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Loxapine 10 mg
Description: Single 10 mg (5th) dose of inhaled loxapine
Study NCT00444028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Placebo (0 mg)
Description: Single placebo dose of inhaled loxapine
Study NCT01584193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subclavian vein puncture
Description: Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
Study NCT01584193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cephalic vein dissection
Description: Central venous access port implementation through cephalic vein dissection and cutdown
Study NCT04709640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Medication Management Intervention
Description: This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
Study NCT02797600 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
Study NCT02797600 — intervention group
Intervention type: OTHER
Intervention: Biological Samples
Description: All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
Study NCT01440348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cruciate ligament reconstruction
Description: Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
Study NCT03876327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal microbial transplantation
Description: Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
Study NCT04693858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Anxiety Learning Modules (CALM)
Description: CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
Study NCT04693858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Anxiety Learning Modules--Relaxation (CALM-R)
Description: CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
Study NCT04819022 — intervention group
Intervention type: DEVICE
Intervention: Acute and post-acute
Description: These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
Study NCT04819022 — intervention group
Intervention type: DEVICE
Intervention: Chronic
Description: These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danoprevir Placebo
Description: Danoprevir Placebo tablet administered orally twice daily
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir Placebo
Description: Ritonavir Placebo tablet administered orally twice daily
Study NCT03362814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin Placebo
Description: Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
Study NCT02470325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Avidekel oil
Description: Enriched Avidekel cannabis oil 20:1 CBD:THC
Study NCT03319004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apply phase lag entropy sensor
Description: apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
Study NCT03970941 — intervention group
Intervention type: OTHER
Intervention: Cost evaluation
Description: The cost for the hospital of the strategy of management will be evaluated.
Study NCT03970941 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The quality of life of patients will be measured.
Study NCT03343834 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological collection
Description: At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation
Study NCT04137731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Current Therapy
Description: IFC treatment after Total Knee Arthroplasty
Study NCT03501095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vocal analysis and Laryngostroboscopy
Description: Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement.
Study NCT01401933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: QD on Days 1 and 13
Study NCT01401933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: QD on Days 5-16
Study NCT01388842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Study NCT01388842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Study NCT01933906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Study NCT04023877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: E2027 oral capsule.
Study NCT01652391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)
Study NCT01652391 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)
Study NCT00314366 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Therapy
Description: Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
Study NCT00314366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (plasma)
Description: Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
Study NCT02549508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake On
Description: The comfort feature 'SensAwake' will be turned on
Study NCT02549508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake Off
Description: The comfort feature 'SensAwake' will be turned off
Study NCT03139890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat (HF-LC-LP) milkshake
Description: During this experimental day, men will receive a high-fat milkshake
Study NCT03139890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (LF-HC-LP) milkshake
Description: During this experimental day, men will receive a high-carbohydrate milkshake
Study NCT03139890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein (LF-LC-HP) milkshake
Description: During this experimental day, men will receive a high-protein milkshake
Study NCT01261858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite
Description: osteoconductive biologic bone cement to be applied upon sternal closure
Study NCT01261858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kryptonite
Description: osteoconductive biologic bone cement to be applied upon sternal closure
Study NCT03709537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Peer Workforce Support
Description: Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency.
Study NCT04137731 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Interferential Current Therapy
Description: IFC treatment after Total Knee Arthroplasty
Study NCT02954393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study NCT02954393 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole active phase
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole healing phase
Description: Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin active phase
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin healing phase
Description: Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos active phase
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos active phase
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos healing phase
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
Study NCT02954393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos healing phase
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).